Inhibition of Tumorigenesis in a Murine B-Cell Lymphoma Transplant Model By c-Myc Complementary Oligonucleotides
- 1 January 1998
- book chapter
- Published by Springer Nature
- Vol. 451, 17-22
- https://doi.org/10.1007/978-1-4615-5357-1_3
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- BCL-2 antisense therapy in patients with non-Hodgkin lymphomaThe Lancet, 1997
- Antisense oligonucleotides: towards clinical trialsTrends in Biotechnology, 1996
- CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma.Proceedings of the National Academy of Sciences, 1996
- Aggressive Chemotherapy in the Treatment of Burkitt's and Non-BurKitt's Undifferentiated LymphomaLeukemia & Lymphoma, 1995
- Prospects for the therapeutic use of antisense oligonucleotides in malignant lymphomasAnnals of Oncology, 1994
- Non–Sequence-Specific Inhibition of Transferrin Receptor Expression in HL-60 Leukemia Cells by Phosphorothioate OligodeoxynucleotidesAntisense Research and Development, 1991
- The automated synthesis of sulfur-containing oligodeoxyribonucleotides using 3H-1,2-benzodithiol-3-one 1,1-dioxide as a sulfur-transfer reagentThe Journal of Organic Chemistry, 1990
- A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1Nature, 1987
- The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic miceNature, 1985